Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and activity of semicarbazide-sensitive amine oxidase

Abstract Leukocytes migrate from the blood into areas of inflammation by interacting with various adhesion molecules on endothelial cells. Vascular adhesion protein-1 (VAP-1) is a glycoprotein expressed on inflamed endothelium where it plays a dual role: it is both an enzyme that oxidizes primary amines and an adhesin that is involved in leukocyte trafficking to sites of inflammation. Although VAP-1 was identified more than 15 years ago, the counterreceptor(s) for VAP-1 on leukocytes has remained unknown. Here we have identified Siglec-10 as a leukocyte ligand for VAP-1 using phage display screenings. The binding between Siglec-10 and VAP-1 was verified by different adhesion assays, and this interaction was also consistent with molecular modeling. Moreover, the interaction between Siglec-10 and VAP-1 led to increased hydrogen peroxide production, indicating that Siglec-10 serves as a substrate for VAP-1. Thus, the Siglec-10–VAP-1 interaction seems to mediate lymphocyte adhesion to endothelium and has the potential to modify the inflammatory microenvironment via the enzymatic end products.

Download Full-text

Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score

The American Journal of Cardiology ◽

10.1016/j.amjcard.2010.11.011 ◽

2011 ◽

Vol 107 (6) ◽

pp. 938-944 ◽

Cited By ~ 22

Author(s):

Sergio Raposeiras-Roubín ◽

Bruno K. Rodiño-Janeiro ◽

Lilian Grigorian-Shamagian ◽

María Moure-González ◽

Ana Seoane-Blanco ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Advanced Glycation End Products ◽

Soluble Receptor ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products

Download Full-text

Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome

BioMed Research International ◽

10.1155/2015/815942 ◽

2015 ◽

Vol 2015 ◽

pp. 1-7 ◽

Cited By ~ 14

Author(s):

Louise J. N. Jensen ◽

Allan Flyvbjerg ◽

Mette Bjerre

Keyword(s):

Acute Coronary Syndrome ◽

Advanced Glycation End Products ◽

Acute Ischemia ◽

Soluble Receptor ◽

Advanced Glycation ◽

Coronary Syndrome ◽

Potential Biomarker ◽

Glycation End Products ◽

End Products ◽

Artery Disease

The receptor of advanced glycation end products (RAGE) and its ligands are linked to the pathogenesis of coronary artery disease (CAD), and circulating soluble receptor of advanced glycation end products (sRAGE), reflecting the RAGE activity, is suggested as a potential biomarker. Elevated sRAGE levels are reported in relation to acute ischemia and this review focuses on the role of sRAGE as a biomarker for the acute coronary syndrome (ACS). The current studies demonstrated that sRAGE levels are elevated in relation to ACS, however during a very narrow time period, indicating that the time of sampling needs attention. Interestingly, activation of RAGE may influence the pathogenesis and reflection in sRAGE levels in acute and stable CAD differently.

Download Full-text